Successful reduced-intensity hematopoietic stem cell transplantation in myelodysplastic syndrome with severe coronary artery disease

International Journal of Hematology
Shigeki KosugiK Sawada

Abstract

A 60-year-old Japanese man with myelodysplastic syndrome (MDS) and effort angina was referred to our clinic for treatment of MDS. The patient was transfusion-dependent and displayed coronary artery disease (CAD) with 99% obstruction of the left anterior descending coronary artery. Treatment comprised reduced-intensity hematopoietic stem cell transplantation with administration of fludarabine phosphate (180 mg/m(2)) and busulfan (8 mg/kg), followed by allogeneic peripheral blood stem cell transplantation from an HLA-matched sister. The regimen was well tolerated, and engraftment occurred rapidly without any therapy-related complications, including cardiovascular attack. Sex chromosome analysis by fluorescence in situ hybridization revealed complete donor chimerism on day 29 for bone marrow cells and on day 59 for peripheral blood leukocytes. The patient became transfusion-independent on posttransplantation day 8. As of 22 months postoperatively, he remains well, with 100% Karnofsky performance status, a limited type of chronic graft-versus-host disease, and no recurrence of disease. The clinical course of the patient suggests that this preparative regimen allows safe allogeneic stem cell transplantation for MDS patients with sev...Continue Reading

References

Jun 1, 1982·British Journal of Haematology·J M BennettC Sultan
May 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B HertensteinM Kochs
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lynn M SchuchterUNKNOWN American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel
Aug 31, 2002·Bone Marrow Transplantation·S Luger, N Sacks
Jan 9, 2003·Lancet·Christof StammGustav Steinhoff
Jan 25, 2003·British Journal of Haematology·David BowenUNKNOWN UK MDS Guidelines Group
May 28, 2003·The American Journal of Cardiology·J Airton ArrudaValter C Lima
Mar 11, 2004·Mayo Clinic Proceedings·Irene M GhobrialMark R Litzow
Jun 29, 2004·International Journal of Hematology·Fu-Sheng Wang, Cathy Trester
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie SchanzDetlef Haase

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.